Juan Chen1, Ji-Ye Yin1, Xiang-Ping Li2, Ying Wang3, Yi Zheng2, Chen-Yue Qian2, Hui He2, Chao Fang2, Zhan Wang4, Yu Zhang2, Ling Xiao1, Sai-Ying Wang2, Wei Zhang1, Hong-Hao Zhou2, Zhao-Qian Liu5. 1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China; Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China. 2. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China. 3. Affiliated Cancer Hospital of XiangYa School of Medicine, Central South University, Changsha, P.R. China. 4. Department of Oncology, Xiangya Hospital, Central South University, Changsha, P.R. China. 5. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, P.R. China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, P.R. China; Hunan Province Cooperation Innovation Center for Molecular Target New Drug Study, Hengyang, P. R. China. Electronic address: liuzhaoqian63@126.com.
Abstract
BACKGROUND: Platinum-based chemotherapy is the main treatment method for lung cancer patients. The genetic polymorphisms of Wnt-inducible signaling pathway protein 1 (WISP1) were reported to be associated with the development of diverse lung diseases. In this study, we aimed to investigate the relationship of WISP1 genetic polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response in Chinese lung cancer patients. MATERIALS AND METHODS: A total of 556 lung cancer patients and 254 healthy controls were enrolled onto this study. The 28 polymorphisms of the WISP1 gene were genotyped by the Sequenom MassARRAY system. RESULTS: We found that WISP1 rs16893344, rs2977530, rs2977537, and rs62514004 (P = .009, .033, .049, and .036, respectively) polymorphisms were related to susceptibility of lung cancer; and WISP1 rs11778573 (P = .023, nonsmokers), rs16893344 (P = .013, ≥ 50 years old), rs2977536 (P = .039, ≥ 50 years old; P = .044, nonsmokers; P = .047, non-small-cell lung cancer, respectively), rs2977549 (P = .013, smokers), and rs62514004 (P = .033, ≥ 50 years old) polymorphisms were significantly associated with platinum-based chemotherapy response in lung cancer patients. CONCLUSION: Genotypes of WISP1 may be novel and useful biomarkers for diagnosis of lung cancer and evaluation of platinum-based chemotherapy response in lung cancer patients.
BACKGROUND:Platinum-based chemotherapy is the main treatment method for lung cancerpatients. The genetic polymorphisms of Wnt-inducible signaling pathway protein 1 (WISP1) were reported to be associated with the development of diverse lung diseases. In this study, we aimed to investigate the relationship of WISP1 genetic polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response in Chinese lung cancerpatients. MATERIALS AND METHODS: A total of 556 lung cancerpatients and 254 healthy controls were enrolled onto this study. The 28 polymorphisms of the WISP1 gene were genotyped by the Sequenom MassARRAY system. RESULTS: We found that WISP1rs16893344, rs2977530, rs2977537, and rs62514004 (P = .009, .033, .049, and .036, respectively) polymorphisms were related to susceptibility of lung cancer; and WISP1rs11778573 (P = .023, nonsmokers), rs16893344 (P = .013, ≥ 50 years old), rs2977536 (P = .039, ≥ 50 years old; P = .044, nonsmokers; P = .047, non-small-cell lung cancer, respectively), rs2977549 (P = .013, smokers), and rs62514004 (P = .033, ≥ 50 years old) polymorphisms were significantly associated with platinum-based chemotherapy response in lung cancerpatients. CONCLUSION: Genotypes of WISP1 may be novel and useful biomarkers for diagnosis of lung cancer and evaluation of platinum-based chemotherapy response in lung cancerpatients.
Authors: Xing Wang; Shabnam Salimi; Zhongliang Deng; James Perry; Kathleen A Ryan; Zhizhen Li; Dongfang Liu; Elizabeth Streeten; Alan R Shuldiner; Mao Fu Journal: Sci Rep Date: 2018-05-08 Impact factor: 4.379